Sumitomo Mitsui DS Asset Management Company Ltd Has $23 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Merck & Co., Inc. (NYSE:MRK) by 1.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 277,220 shares of the company’s stock after acquiring an additional 3,706 shares during the period. Merck & Co., Inc. makes up approximately 0.7% of Sumitomo Mitsui DS Asset Management Company Ltd’s holdings, making the stock its 27th biggest holding. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Merck & Co., Inc. were worth $22,995,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Insight Wealth Strategies LLC increased its stake in Merck & Co., Inc. by 6.1% during the 3rd quarter. Insight Wealth Strategies LLC now owns 8,784 shares of the company’s stock worth $729,000 after purchasing an additional 502 shares in the last quarter. LVW Advisors LLC increased its stake in Merck & Co., Inc. by 3.0% during the 3rd quarter. LVW Advisors LLC now owns 5,859 shares of the company’s stock worth $486,000 after purchasing an additional 169 shares in the last quarter. Wealthcare Advisory Partners LLC increased its stake in Merck & Co., Inc. by 0.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 16,881 shares of the company’s stock worth $1,400,000 after purchasing an additional 137 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in Merck & Co., Inc. by 2.2% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 3,527,862 shares of the company’s stock worth $292,637,000 after purchasing an additional 75,599 shares in the last quarter. Finally, Private Wealth Partners LLC increased its stake in Merck & Co., Inc. by 15.2% during the 3rd quarter. Private Wealth Partners LLC now owns 285,875 shares of the company’s stock worth $23,713,000 after purchasing an additional 37,671 shares in the last quarter. Institutional investors and hedge funds own 73.18% of the company’s stock.

In other Merck & Co., Inc. news, insider Sanat Chattopadhyay sold 10,380 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $83.01, for a total transaction of $861,643.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Frank Clyburn sold 18,876 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $81.55, for a total value of $1,539,337.80. Following the sale, the executive vice president now directly owns 99,639 shares of the company’s stock, valued at approximately $8,125,560.45. The disclosure for this sale can be found here. Insiders have sold a total of 280,529 shares of company stock valued at $22,761,633 in the last ninety days. Insiders own 0.28% of the company’s stock.

A number of analysts recently issued reports on MRK shares. Truist started coverage on Merck & Co., Inc. in a research note on Friday, October 23rd. They set a “buy” rating and a $96.00 target price for the company. Mizuho reissued a “buy” rating on shares of Merck & Co., Inc. in a research note on Tuesday, September 22nd. SVB Leerink raised their price target on shares of Merck & Co., Inc. from $100.00 to $103.00 and gave the stock an “outperform” rating in a research note on Thursday. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Finally, ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $95.36.

Shares of NYSE MRK traded down $0.68 during trading hours on Friday, hitting $75.21. The company had a trading volume of 10,589,124 shares, compared to its average volume of 10,589,178. The stock has a market capitalization of $190.22 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 1.98 and a beta of 0.43. The company has a quick ratio of 1.05, a current ratio of 1.32 and a debt-to-equity ratio of 0.94. Merck & Co., Inc. has a 1-year low of $65.25 and a 1-year high of $92.64. The firm’s 50 day moving average is $81.43 and its 200-day moving average is $80.46.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, October 27th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.44 by $0.30. The company had revenue of $12.55 billion during the quarter, compared to the consensus estimate of $12.21 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.51 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 5.7 earnings per share for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What is the Difference Between Common Shares and Convertible Shares?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.